Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A Para A of Schedule III and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Emcure Pharmaceuticals has informed that NSE Sustainability Ratings & Analytics, a SEBI registered Environmental, Social, and Governance (ESG) Rating Provider, has voluntarily and independently assigned ESG rating of 21 to the Company, for the Financial Year 2024-25, based on information available in public domain. This disclosure is being made based on the information received by the Company vide email dated May 07, 2026, about such rating.
The above information is a part of company’s filings submitted to BSE.
